• Capital increase for an indicative amount of €15 million with possible extension option up to €5 million, consisting of (1) a private placement to institutional investors and certain founders and (2) a public offering via the PrimaryBid platform
• Participation of existing shareholders INKEF Capital and EQT Life Sciences (for €3 million), as well as certain founders, members of management and the Board of Directors (for approximately €1 million) in the Accelerated Construction of the Order Book
• Issue price: €4.50 per share, i.e. a discount of 16.6% compared to the weighted average price of the last 30 days
• Closing of the PrimaryBid offer and the Private Placement on March 21, 2024 before the market opens
• The funds raised will mainly be allocated to financing the development and regulatory approval of ARC-IM® and ARC-EX®, to the establishment of a commercial organization for the launch in the United States of ARC-EX, capacity building in terms of quality and financing of working capital needs.
Find the full press release below: